The development of the transgenic mouse that expresses high levels of mutant APP v717-F with consequent development of diffuse and neuritic plaques is the most promising animal model of AD, and represents a breakthrough in the investigation of the inflammatory hypothesis of AD. Using this animal model it is now feasible to determine the extent and sequence of activation of inflammatory pathways by both diffuse and neuritic amyloid plaques. The proposed Pilot Project explores the role of complement system and other immuno-inflammatory molecules in brain of the amyloid precursor protein (APP)-v717-F transgenic mice bearing AD-type neuropathology and control littermates. If it can be shown that C-system activation, similar to that seen in AD is present in the brain of these mice, it will be feasible to propose future studies of anti-inflammatory interventions in the mice. These pilot studies may provide rationales, potential sites of action and timing for controlling immuno-inflammatory mechanisms in AD brain.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Small Research Grants (R03)
Project #
1R03AG014239-01
Application #
2002163
Study Section
Special Emphasis Panel (SRC (82))
Project Start
1996-09-30
Project End
1999-09-29
Budget Start
1996-09-30
Budget End
1999-09-29
Support Year
1
Fiscal Year
1996
Total Cost
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Psychiatry
Type
Schools of Medicine
DUNS #
114400633
City
New York
State
NY
Country
United States
Zip Code
10029
Mukherjee, Piali; Thomas, Sunil; Pasinetti, Giulio Maria (2008) Complement anaphylatoxin C5a neuroprotects through regulation of glutamate receptor subunit 2 in vitro and in vivo. J Neuroinflammation 5:5
Zhao, Zhong; Xiang, Zhongmin; Haroutunian, Vahram et al. (2007) Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. Neurobiol Aging 28:824-30
Ho, L; Guo, Y; Spielman, L et al. (2001) Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique. Neurosci Lett 298:191-4
Mukherjee, P; Pasinetti, G M (2001) Complement anaphylatoxin C5a neuroprotects through mitogen-activated protein kinase-dependent inhibition of caspase 3. J Neurochem 77:43-9
Ho, L; Purohit, D; Haroutunian, V et al. (2001) Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. Arch Neurol 58:487-92
Mukherjee, P; Pasinetti, G M (2000) The role of complement anaphylatoxin C5a in neurodegeneration: implications in Alzheimer's disease. J Neuroimmunol 105:124-30
Kelley, K A; Ho, L; Winger, D et al. (1999) Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am J Pathol 155:995-1004
Osaka, H; McGinty, A; Hoepken, U E et al. (1999) Expression of C5a receptor in mouse brain: role in signal transduction and neurodegeneration. Neuroscience 88:1073-82
Battaini, F; Pascale, A; Lucchi, L et al. (1999) Protein kinase C anchoring deficit in postmortem brains of Alzheimer's disease patients. Exp Neurol 159:559-64
Osaka, H; Mukherjee, P; Aisen, P S et al. (1999) Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J Cell Biochem 73:303-11

Showing the most recent 10 out of 17 publications